The success of target validation and lead optimization depends heavily on how closely a biological model mimics the complexities of human disease. Discrepancies between experimental environments and clinical pathology often lead to late-stage attrition in drug development.
In this webinar, Melanie Homberg and Kevin Grady will discuss strategies for integrating high-throughput CRISPR screens and advanced biological models to accelerate drug discovery workflows.
Topics to be covered:
- Criteria for selecting disease-relevant models to improve target validation
- High-throughput CRISPR screening methods for identifying novel targets
- Advanced in vitro and in vivo models for enhancing translational success
- Practical approaches to align model selection with tissue and safety requirements
Wednesday, April 22nd 2026 | 11:00 AM – 12:00 PM Eastern Time
This webinar will be available to view live and on demand.
Speakers
Melanie Homberg, PhD
Market Development Manager
Lonza
Kevin Grady
Associate Director, Market Strategy
Lonza
